BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9378159)

  • 1. Molecular aspects of breast and ovarian cancer.
    Giannios J; Ioannidou-Mouzaka L
    Eur J Gynaecol Oncol; 1997; 18(5):387-93. PubMed ID: 9378159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular aspects of ovarian cancer.
    Wenham RM; Lancaster JM; Berchuck A
    Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):483-97. PubMed ID: 12413930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene targets of antisense therapies in breast cancer.
    Yang DC; Elliott RL; Head JF
    Expert Opin Ther Targets; 2002 Jun; 6(3):375-85. PubMed ID: 12223074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of breast and ovarian cancer.
    Narod SA
    Br Med Bull; 1994 Jul; 50(3):656-76. PubMed ID: 7987646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
    Feki A; Irminger-Finger I
    Crit Rev Oncol Hematol; 2004 Nov; 52(2):103-16. PubMed ID: 15501075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
    Badora A; Kaleta B; Nowara E; Sikora-Jopek M; Budryk M; Smok-Ragankiewicz A
    Ginekol Pol; 2013 Oct; 84(10):892-6. PubMed ID: 24273914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inherited susceptibility to breast and ovarian cancer.
    Diamond TM; Sutphen R; Tabano M; Fiorica J
    Curr Opin Obstet Gynecol; 1998 Feb; 10(1):3-8. PubMed ID: 9484622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetics of breast and ovarian cancer.
    Ford D; Easton DF
    Br J Cancer; 1995 Oct; 72(4):805-12. PubMed ID: 7547224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular genetics of hereditary breast carcinoma].
    Hampl M; Chang-Claude J; Schwarz P; Saeger HD; Schackert HK
    Zentralbl Chir; 1997; 122(2):67-73. PubMed ID: 9173760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
    Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
    Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour biological features of BRCA1-induced breast and ovarian cancer.
    Jóhannsson OT; Idvall I; Anderson C; Borg A; Barkardóttir RB; Egilsson V; Olsson H
    Eur J Cancer; 1997 Mar; 33(3):362-71. PubMed ID: 9155518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
    Skasko E; Paszko Z; Niwińska A; Kwiatkowska E; Kruczek A; Pieńkowski T
    Eur J Gynaecol Oncol; 2004; 25(4):470-4. PubMed ID: 15285306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer genes: therapeutic strategies.
    Holt JT
    Ann N Y Acad Sci; 1997 Dec; 833():34-41. PubMed ID: 9616738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
    Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
    Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetics of ovarian cancer: molecular biology and clinical application.
    DePasquale SE; Giordano A; Donnenfeld AE
    Obstet Gynecol Surv; 1998 Apr; 53(4):248-56. PubMed ID: 9560835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer susceptibility testing: past, present and future.
    Goldberg JI; Borgen PI
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.